Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
UPPSALA, Sweden, July 18, 2023 /PRNewswire/ -- The patent win critical enabler for future growth Q2 2023 highlights › Total…
The patent win critical enabler for future growth
Q2 2023 highlights
› Total net revenues of SEK 157.7 m (147.8)
› …
Uppsala, Sweden – July 7, 2023 – As previously communicated Orexo will announce the Interim Report for the second quarter…
NEW DELHI (dpa-AFX) - Orexo AB (ORXOY) said that the US District Court for the District of New Jersey ruled…
· The court found Orexo´s patents valid and infringed by Sun
· The outcome once again confirms the strength…
Orexo is breaking new ground in the area of anaphylaxis with OX640, an innovative nasal powder epinephrine product. In this…
UPPSALA, Sweden, April 27, 2023 /PRNewswire/ -- Focusing operations on Orexo´s strengths Q1 2023 highlights Total net revenues of SEK…
Focusing operations on Orexo´s strengths
Q1 2023 highlights
· Total net revenues of SEK 158.8 m (159.4)
· EBITDA of…
Uppsala, Sweden – April 20, 2023 – As previously communicated Orexo will announce the Interim Report for the first quarter…
Uppsala, Sweden – April 3, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124,…
UPPSALA, Sweden, March 28, 2023 /PRNewswire/ -- Orexos Annual and Sustainability Report for 2022 has been published and can be…
Uppsala, Sweden - March 28, 2023 – Orexos Annual and Sustainability Report for 2022 has been published and can be…
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the…
Uppsala, Sweden – March 15, 2023 – Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual…
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are…
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to…
OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten…
· OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl
· Nine out…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
UPPSALA, Sweden, Jan. 26, 2023 /PRNewswire/ -- Important steps forward in a challenging environment Q4 2022 highlights Total net revenues…
Important steps forward in a challenging environment
Q4 2022 highlights
· Total net revenues of SEK 156.1 m (144.0)
·…
Orexo has successfully formulated Covid-19 spike protein in the proprietary drug delivery platform amorphOX®, showing excellent protein stability Orexo has…
· Orexo has successfully formulated Covid-19 spike protein in the proprietary drug delivery platform amorphOX®, showing excellent protein stability
…
UPPSALA, Sweden, Nov. 3, 2022 /PRNewswire/ -- Advancing the pipeline facilitating future growth Q3 2022 highlights Total net revenues of…
Advancing the pipeline facilitating future growth
Q3 2022 highlights
· Total net revenues of SEK 161.0 m (145.9)
·…
Study evaluating efficacy of MODIA®, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with opioid…
· Study evaluating efficacy of MODIA®, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with…
UPPSALA, Sweden, Oct. 26, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today welcomes Edward (Ed) Kim, M.D., as new…
Uppsala, Sweden – October 26, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today welcomes Edward (Ed) Kim, M.D., as new…
UPPSALA, Sweden, Oct. 17, 2022 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) that will take place on April…
Uppsala, Sweden – October 17, 2022 – Prior to the Annual General Meeting (AGM) that will take place on April…
All four investigational formulations of OX640 were extensively absorbed and rapidly achieved clinically relevant plasma levels of epinephrine Data available…
· All four investigational formulations of OX640 were extensively absorbed and rapidly achieved clinically relevant plasma levels of epinephrine
…